Patients

More... "BostonGene Genomic testing can help save your life like it has saved mine."

In May 2021, 60-year-old Elvia went in for a routine mammogram. Because Elvia has a history of fibrosis, she was not surprised that her doctors requested additional studies. She was then advised to have a biopsy. A standard IHC testing from that biopsy was consistent with a diagnosis of triple-negative breast cancer. Based on these results, Elvia started neoadjuvant treatment with pembrolizumab plus chemotherapy and plans for surgery were underway. However, scheduling surgery proved to be challenging due to a COVID diagnosis and her surgeon’s availability so Elvia transferred her care in late September 2021. Her new physician collected more scans, which indicated the tumor was progressing on the current regimen. To see a complete 360° view of her tumor, her doctor requested the BostonGene Tumor Portrait^TM test, which revealed the cancer was not triple-negative and was, in fact, HER2 positive. When thinking back, Elvia says, “I cried when I heard the diagnosis.” These findings offered HER2-targeted treatment options, prompting a change to TCHP neoadjuvant therapy in January 2022. Repeat scans two months later during neoadjuvant therapy demonstrated 80% tumor shrinkage with this new HER2-directed treatment plan. After completion of neoadjuvant therapy, Elvia underwent surgery and was found to have a complete pathological response. For Elvia, integrated WES and RNA-seq analysis uncovered significant HER2 findings that were not found by the initial IHC test. When asked how she’s doing today, Elvia says, “Great, and I’ve been great since I got this new diagnosis. Everything was suddenly clear, like I woke up from a dream.” “Genetic testing should be standard for all cancer patients. It helped to find the best treatment for my case.“

While on a business trip in South Carolina during the summer of 2018, Curtis woke in the middle of the night with severe epigastric pain. He immediately found himself at the local hospital emergency room undergoing a series of tests that ultimately revealed he had cancer – non-Hodgkins lymphoma. In August 2020, Curtis was back in the hospital after his doctor found lymphoma was progressing in his lungs. With standard chemotherapy options historically not effective, it was time for him to seek other therapy options.  Determined to find an alternative treatment, Curtis’ doctor suggested BostonGene conduct genomic testing.  The results showed a very high expression of CD30, which is atypical for his type of lymphoma as well as unusual immune changes in his tumor.  Based on this rare finding, Brentuximab, an antibody-drug conjugate medication that selectively targets tumor cells expressing the CD30 antigen, was added to a ‘cocktail’ of immune agents that Curtis received. In December 2020, after only four months of treatment, Curtis’ scans showed no evidence of a tumor. “A cancer diagnosis changes your perspective on what is important in life. Cancer leads to a total paradigm shift of priorities in life.  If my doctor had not recommended BostonGene’s test, or we didn’t learn any new information on my cancer, I would not be here right now spending time with my family and friends.  I feel very blessed that this is the way it worked out,” says Curtis. "BostonGene gave me hope at a point where there was no path to take."